Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Hims & Hers Health in the transaction. Hims & Hers Health, a multi-specialty telehealth platform, announced its acquisition...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Openwater in the transaction. Openwater, a medical technology company, announced it secured $100 million financing from new and...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Radar Therapeutics on the deal, and Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Alamar Biosciences in the transaction. Alamar Biosciences announced it raised $128 million in Series C financing round. The financing...
You must be a Standard 1 Year member to access this content.
Baker McKenzie represented LiveRamp in the transaction, and Gunderson Dettmer represented Habu. LiveRamp (NYSE: RAMP), the leading data collaboration platform, today announced that it has entered...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Star Therapeutics in the transaction. Star Therapeutics announced its oversubscribed $90 million Series C financing to continue growth of its...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Hallow on the deal. Hallow, a Catholic meditation and prayer app, announced the close of an additional $50 million in Series C funding bringing the...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Lightspeed Venture Partners on the deal while Mintz represented TRIANA Biomedicines. Lightspeed Venture Partners co-led the $110 million...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Neuron23 on the deal. Neuron23, a biotechnology company, announced its $100 million Series C financing led by SoftBank Vision Fund 2. Neuron23 focuses on...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer and Skadden advised Anaplan on the deal. Kirkland and Ellis and Cadwalader, Wickersham & Taft advised Thoma Bravo. Latham & Watkins represented the direct...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Electra Therapeutics on the deal. Electra Therapeutics, a clinical-stage biotechnology company, announced its $84 million Series B financing co-led...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Seismic Therapeutic, Inc. on the deal while Gunderson Dettmer represented Lightspeed Venture Partners. Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for...
You must be a Standard 1 Year member to access this content.
